Research & Clinical Trials

NPDR

DRCR AF
A triple-masked, randomized trial to evaluate the effect of Fenofibrate, a cholesterol medication, compared with placebo for prevention of diabetic retinopathy (DR) worsening through 4 years of follow-up in eyes with mild to moderately severe non-proliferative diabetic retinopathy (NPDR) and no CI-DME at baseline, DRSS score of 35-47, recruiting in Austin. Seeking patients with Type 1 or 2 diabetes, no prior DME or DR treatment (other than focal/grid laser at least 12 months prior), history of intraocular anti-VEGF or corticosteroid treatment within the prior year for any indication is exclusionary, <80 years old, BCVA 20/25 or better.

DME

Thulite(1485-0018)
A phase 2 randomized, double-masked, placebo-controlled, parallel-group, multicentre study evaluating the efficacy and safety of 3 dosing regiments of oral BI 1825368 compared with placebo in participants with centre-involved diabetic macular edema (DME) for 48 weeks of treatment. Seeking participants that are ≥ 18 years of age, diagnosis mellitus (DM) with either type 1 or type 2, a HbA1c <12% treated with stable medication for at least 30 days prior to Day 1, CST ≥ 320µm for male, CST ≥ 305µm for females, BCVA between 24 and 78 letter (approx. 20/320 to 20/32 Snellen equivalent). No starting of new medication at the time of screening and baseline.

wAMD

Achieve
A randomized, partially masked Phase 3b study evaluating long-term efficacy after subretinal surabgene lomparvovec (ABBV-RGX-314) administration, compared to PRN intravitreal ranibizumab given per protocol specified criteria.

KLRS-100 (PAUSED)
A phase 1, open-label clinical trial to establish the safety, tolerability, dose range, and pharmacokinetic profile of intravitreal injection of TH103 in patients with neovascular age-related macular degeneration (nAMD). Part 1 of the study includes a single administration ascending dose escalation study to identify the maximum tolerated dose (MTD) of TH103. In Part 2 of the study, the drying effect of TH103 is evaluated as a maintenance therapy following aflibercept induction. Seeking treatment-naïve patients with subfoveal or juxtafoveal/extrafoveal macular neovascularization with foveal involvement, BCVA between 20/40 to 20/200 and CST minimal thickness of 325 μm.

Malbec (MK-8748-002)
A double-masked phase ⅔ study to evaluate the efficacy and safety of IVT EYE201/MK-8748 compared to aflibercept in participants with NVAMD. Seeking patients that are treatment-naive, ≥50 years of age diagnosed with CNV secondary to AMD, including subfoveal, juxtafoveal, and extrafoveal lesions of RAP. CNV area in the study eye must be at least 50% of total lesion size at screening in FA. For these patients a BCVA ETDRS letter score of 24 to 78 (20/320 to 20/32 Snellen equivalent) in the Study Eye is required.

NOVA-1 (RYE888-E001)
A phase 1/2 dose-escalation and randomized, parallel-group study evaluating the safety, preliminary treatment effects, and durability of the AR-14034 sustained-release vs. intravitreal anti-VEGF in patients with nAMD. Seeking treatment-naive or recently diagnosed patients (12 months). Previously treated patients must have had ≤ 3 anti-VEGF injections in the last 6 months, with improved macular edema or ≥50µm retinal thickness reduction. Must be ≥ 50 years old, have CNV involving the macula, BCVA 80-35 letters (20/25-20/200), and CST >300µm and <400µm.

Super Tuscan (EYE-RES-104) (PAUSED)
A phase 2, randomized dose-masked study to evaluate the safety, tolerability, and efficacy of IVT EYE 103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). For nAMD inclusion criteria: Seeking treatment naïve participants with subfoveal CNV secondary to AMD. Must be > 50 years of age & diagnosis must have been made within 21 days prior to the Day 1 study treatment. Have an ETDRS BCVA letter score between 75 & 35 (approx. 20/32 to 20/200 Snellen equivalent. Have a CST ≥ 325 µm in the study eye. For BRVO: Seeking treatment naïve patients with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of screening. Have a BCVA letter score between 75 and 24 (approx. 20/32 to 20/320 Snellen equivalent), and CST of ≥ 325 µm in study eye.

GA

Character Biosciences (CTX114-CS101)
A phase 1, open-label clinical study to evaluate the safety, tolerability, and pharmacokinetics of CTX114 injection in participants with Geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Seeking patients that are 60 years and old, GA total lesion ≥ 0.50mm2 with hyperautofluorescence, & BCVA of 24 to 78 letters (20/320 to 20/32 approx snellen).

Galaxy (ONL1204-GA-002)
A phase 2 multicenter, randomized, double-masked, sham-controlled, reference-arm study to evaluate efficacy and safety of ONL1204 in patients with Geographic Atrophy (GA) associated with Age-related Macular Degeneration (AMD). Seeking participants that are 55 years or older with non-foveal GA associated with AMD without eMNV in the study eye, GA should measure ≥0.85 disc area (2.125 mm²) and ≤8.05 DA (20.125 mm²), with at least one lesion measuring ≥0.425 DA (1.063 mm²) if multifocal. Prior or current IVT treatment that is regionally approved must have a 12 week washout prior to screening.

Gallop (APL3007-GA-201)
A phase 2, randomized, placebo-controlled study evaluating multidose APL-3007 with Syforve/Pegcetacoplan (APL-2) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Seeking patients aged ≥60 years, clinical diagnosis of GA in one or both eyes, BCVA of 50 letters or better (approx. 20/100 snelled equivalent). Prior treatment with Syfovre in the study eye for 6-8 week intervals over at least 6 months, but no longer than 24 months. GA lesions must be ≥2.5 mm² and <17.5 mm² (1–7 DA), with at least one lesion ≥1.25 mm² (0.5 DA) if multifocal, and fully visualized on OCT. Must have adequate ocular media clarity, dilation, and fixation for high-quality imaging.

Sienna (R3918-AMD-2326)
A multicenter, randomized, double-masked, placebo-controlled phase 3 study of efficacy, safety, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in participants with Geographic Atrophy secondary to Age-Related Macular Degeneration. Seeking patients ≥50 years of age with a diagnosis of GA of the macula secondary to AMD, not involving the foveal center point, with a BCVA EDTRS of 55 letters or better (20/80 Snellen equivalent) and a total GA area measuring ≥2.5 mm2 and ≤17.5 mm2 in the study eye. Prior or current IVT treatment of any kind for any indication in either eye must have a washout period of ≥6 months.

Vienna (R3918-AMD-2501)
A phase 1 dose-escalation and repeated-dose study of the safety and tolerability of intravitreal pozelimab (anti-C5 monoclonal antibody) in participants with geographic atrophy. This study consists of two stages: a single-dose stage (Part A) and a repeated-dose stage (Part B). Seeking patients that are ≥ 50 , GA measuring 2.5 mm2 or larger that can be completely captured by FAF, and BCVA ≤ 60 letters (20/63 or worse).

BRVO

Super Tuscan (EYE-RES-104) (PAUSED)
A phase 2, randomized dose-masked study to evaluate the safety, tolerability, and efficacy of IVT EYE 103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). For nAMD inclusion criteria: Seeking treatment naïve participants with subfoveal CNV secondary to AMD. Must be > 50 years of age & diagnosis must have been made within 21 days prior to the Day 1 study treatment. Have an ETDRS BCVA letter score between 75 & 35 (approx. 20/32 to 20/200 Snellen equivalent. Have a CST ≥ 325 µm in the study eye. For BRVO: Seeking treatment naïve patients with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of screening. Have a BCVA letter score between 75 and 24 (approx. 20/32 to 20/320 Snellen equivalent), and CST of ≥ 325 µm in study eye.

Other

Compass (AU-011-301)
A phase 3 trial to evaluate efficacy and safety of Belzupacap Sarotalocan (AU-011) treatment compared to sham control in subjects with primary indeterminate lesions or small choroidal melanoma, recruiting in Austin. Seeking patients with BCVA 20/50 or better, IL/CM has a thickness ≥0.5 mm and ≤2.5 mm on B-scan and LBD ≤10.0 mm on true-color FP, observation-only could be an appropriate standard of care for the patient, be treatment naïve for their IL/CM, no evidence of metastatic disease.

Character Biosciences (CTX203-CS101)
A phase 1, open-label clinical study to evaluate the safety, tolerability, and pharmacokinetics of CTX203 injection in participants with dry age-related macular degeneration (AMD). We are currently only enrolling the study design part B: Multiple Ascending Dose (MAD), in which 3 IVT injections of CTX203 are administered in the study eye 28 days apart. First enrollee, deemed sentinel participants, will receive the 1st IVT injection of IP at 30 ug with subsequent injections. Further, 14 days after the sentinels 1st injection. The second cohort will enroll if safety is deemed acceptable based on safety data accumulation by Day 14. Seeking patients that are 60 years or older, at least 1 soft drusen ≥ 125 um and drusen volume ≥ 0.2 mm2 within 5-6 radius of fovea, EDTRS BCVA score ≥ 34 and ≤ 78 (20/200 to 20/32 approx snellen.),BCVA 20/200+ in FE, as well as 2-3 years of prior OCT imaging, medical history, and fundus imaging.

OptimUM-10 (IDE196-010)
A phase 3, randomized, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma. Seeking patients that are 18 years or older, at high risk with at least ONE of the following: Monosomy 3, Class 2 GEP, Stage 3AJCC. For Cohort 1 (PB): have a diagnosis of primary UM and being considered for treatment with PB and the following tumor characteristics: Tumor thickness ≥ 4 mm and ≤ 6 mm.

Peak (KSMP001-S1) & Pinnacle (KSMP001-S2)
A phase 3, multicenter platform study, randomized, double-masked, and sham-controlled studies to evaluate the efficacy and safety of intravitreal Tabirafusp Alfa (KSI-101) in patients with Macular Edema Secondary to Inflammation (MESI). For Peak, seeking patients that are ≥ 18 years of age, MESI, with a CST of ≥ 400 microns in study eye, BCVA ETDRS score of ≥ 25 and ≤78 letters (approx 20/25 and 20/320 Snellen equivalent) in the study eye, active macular leakage in study eye, and diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the study eye. For Pinnacle, seeking patients that are ≥ 18 years of age, MESI, with a CST of ≥ 320 and <400 microns in study eye, BCVA score of ≥25 and ≤78 ETDRS letters (approx 20/25 and 20/320 Snellen equivalent) in the study eye, OR patients with MESI, CST of ≥400 microns and BCVA score of ≥71 and ≤78 ETDRS letters (between 20/25 and 20/40 Snellen equivalent) in the study eye. As well as active macular leakage and diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the SE. Patients referred will complete one screening that encompasses both studies and will then randomize into one study or the other based on CST and BCVA.

Upcoming

Aquarius (ADVM-022-13)
A phase 3, double-masked, multicenter, randomized, active-comparator-controlled study to evaluate the efficacy and safety of Ixo-vec in patients with nAMD. Seeking patients that are 50 years and older, IRF or SRF at screening from wAMD, BCVA between 35 & 78 letters (20/32 to 20/200) in SE, and BCVA ≥ 35 (20/200 +) in FE.

wAMD

Kalaris Therapeutics, Inc. (Protocol KLRS-100) “KLRS-100 - wAMD” (PAUSED)
Phase 3, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 (a fusion protein targeting VEGF-C and VEGF-D) in Combination with Lucentis, Compared with Lucentis Alone

Super Tuscan (EYE-RES-104) (PAUSED)
A phase 2, randomized dose-masked study to evaluate the safety, tolerability, and efficacy of IVT EYE 103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). For nAMD inclusion criteria: Seeking treatment naïve participants with subfoveal CNV secondary to AMD. Must be > 50 years of age & diagnosis must have been made within 21 days prior to the Day 1 study treatment. Have an ETDRS BCVA letter score between 75 & 35 (approx. 20/32 to 20/200 Snellen equivalent. Have a CST ≥ 325 µm in the study eye. For BRVO: Seeking treatment naïve patients with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of screening. Have a BCVA letter score between 75 and 24 (approx. 20/32 to 20/320 Snellen equivalent), and CST of ≥ 325 µm in study eye.

GA

ADX-038-100 (PAUSED)
A phase 2, randomized, masked, placebo-controlled study of subcutaneously administered ADX-038 in participants with Geographic Atrophy (GA). Seeking patients that are 56-100, GA Lesion ≥ 2.5 and ≤ 12.5 mm2 (one lesion within 1.5 radius ring around the fovea, if multifocal, one lesion must be ≥ 1.25 mm2), and BCVA (≥20/400), BCVA (20/100) if GA is subfoveal.

Gallop (APL3007-GA-201)
A phase 2, randomized, placebo-controlled study evaluating multidose APL-3007 with Syforve/Pegcetacoplan (APL-2) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Seeking patients aged ≥60 years, clinical diagnosis of GA in one or both eyes, BCVA of 50 letters or better (approx. 20/100 snelled equivalent). Prior treatment with Syfovre in the study eye for 6-8 week intervals over at least 6 months, but no longer than 24 months. GA lesions must be ≥2.5 mm² and <17.5 mm² (1–7 DA), with at least one lesion ≥1.25 mm² (0.5 DA) if multifocal, and fully visualized on OCT. Must have adequate ocular media clarity, dilation, and fixation for high-quality imaging.

Sienna (R3918-AMD-2326)
A multicenter, randomized, double-masked, placebo-controlled phase 3 study of efficacy, safety, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in participants with Geographic Atrophy secondary to Age-Related Macular Degeneration. Seeking patients ≥50 years of age with a diagnosis of GA of the macula secondary to AMD, not involving the foveal center point, with a BCVA EDTRS of 55 letters or better (20/80 Snellen equivalent) and a total GA area measuring ≥2.5 mm2 and ≤17.5 mm2 in the study eye. Prior or current IVT treatment of any kind for any indication in either eye must have a washout period of ≥6 months.
BRVO

Super Tuscan (EYE-RES-104) (PAUSED)
A phase 2, randomized dose-masked study to evaluate the safety, tolerability, and efficacy of IVT EYE 103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). For nAMD inclusion criteria: Seeking treatment naïve participants with subfoveal CNV secondary to AMD. Must be > 50 years of age & diagnosis must have been made within 21 days prior to the Day 1 study treatment. Have an ETDRS BCVA letter score between 75 & 35 (approx. 20/32 to 20/200 Snellen equivalent. Have a CST ≥ 325 µm in the study eye. For BRVO: Seeking treatment naïve patients with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of screening. Have a BCVA letter score between 75 and 24 (approx. 20/32 to 20/320 Snellen equivalent), and CST of ≥ 325 µm in study eye.

Other

Pinnacle/ Peak-MESI
A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Upcoming

Achieve - wAMD
a randomized, partially masked Phase 3b study evaluating long-term efficacy after subretinal surabgene lomparvovec (ABBV-RGX-314) administration, compared to PRN intravitreal ranibizumab given per protocol specified criteria.

Helios-3 - NPDR

Torrontes - wAMD

wAMD

Aquarius (ADVM-022-13)
A phase 3, double-masked, multicenter, randomized, active-comparator-controlled study to evaluate the efficacy and safety of Ixo-vec in patients with nAMD. Seeking patients that are 50 years and older, IRF or SRF at screening from wAMD, BCVA between 35 & 78 letters (20/32 to 20/200) in SE, and BCVA ≥ 35 (20/200 +) in FE.

NOVA-1 (RYE888-E001)
A phase 1/2 dose-escalation and randomized, parallel-group study evaluating the safety, preliminary treatment effects, and durability of the AR-14034 sustained-release vs. intravitreal anti-VEGF in patients with nAMD. Seeking treatment-naive or recently diagnosed patients (12 months). Previously treated patients must have had ≤ 3 anti-VEGF injections in the last 6 months, with improved macular edema or ≥50µm retinal thickness reduction. Must be ≥ 50 years old, have CNV involving the macula, BCVA 80-35 letters (20/25-20/200), and CST >300µm and <400µm.

Super Tuscan (EYE-RES-104) (PAUSED)
A phase 2, randomized dose-masked study to evaluate the safety, tolerability, and efficacy of IVT EYE 103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). For nAMD inclusion criteria: Seeking treatment naïve participants with subfoveal CNV secondary to AMD. Must be > 50 years of age & diagnosis must have been made within 21 days prior to the Day 1 study treatment. Have an ETDRS BCVA letter score between 75 & 35 (approx. 20/32 to 20/200 Snellen equivalent. Have a CST ≥ 325 µm in the study eye. For BRVO: Seeking treatment naïve patients with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of screening. Have a BCVA letter score between 75 and 24 (approx. 20/32 to 20/320 Snellen equivalent), and CST of ≥ 325 µm in study eye.

BRVO

Super Tuscan (EYE-RES-104) (PAUSED)
A phase 2, randomized dose-masked study to evaluate the safety, tolerability, and efficacy of IVT EYE 103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). For nAMD inclusion criteria: Seeking treatment naïve participants with subfoveal CNV secondary to AMD. Must be > 50 years of age & diagnosis must have been made within 21 days prior to the Day 1 study treatment. Have an ETDRS BCVA letter score between 75 & 35 (approx. 20/32 to 20/200 Snellen equivalent. Have a CST ≥ 325 µm in the study eye. For BRVO: Seeking treatment naïve patients with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of screening. Have a BCVA letter score between 75 and 24 (approx. 20/32 to 20/320 Snellen equivalent), and CST of ≥ 325 µm in study eye.

GA

Gallop (APL3007-GA-201)
A phase 2, randomized, placebo-controlled study evaluating multidose APL-3007 with Syforve/Pegcetacoplan (APL-2) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Seeking patients aged ≥60 years, clinical diagnosis of GA in one or both eyes, BCVA of 50 letters or better (approx. 20/100 snelled equivalent). Prior treatment with Syfovre in the study eye for 6-8 week intervals over at least 6 months, but no longer than 24 months. GA lesions must be ≥2.5 mm² and <17.5 mm² (1–7 DA), with at least one lesion ≥1.25 mm² (0.5 DA) if multifocal, and fully visualized on OCT. Must have adequate ocular media clarity, dilation, and fixation for high-quality imaging.

Upcoming

4Front-2 - wAMD

DRCR “Protocol AF”

ClinicalTrials.gov Identifier: NCT04661358

A Triple-masked, Randomized trial to Evaluate the effect of Fenofibrate, a cholesterol medication, compared with placebo for prevention of diabetic retinopathy (DR) worsening.

Valo Health (Protocol OPL-0401-201) “Spectra”
ClinicalTrials.gov Identifier: NCT05393284

Phase 2 study to evaluate the safety and efficacy of OPL-0401 in patients with non-proliferative diabetic retinopathy OPL-0401 is an oral, small molecule ROCK1/2 inhibitor in development for the treatment of diabetic retinopathy.

Retina Consultants of Texas (Protocol MA00832514) “Magic”
ClinicalTrials.gov Identifier: NCT05383209

Faricimab for retinal non-perfusion associated with non-proliferative diabetic retinopathy: the Magic phase 2, multi-center, open-label, randomized controlled trial.

Kodiak Sciences, Inc. (Protocol KS301P108) “Glow2”
ClinicalTrials.gov Identifier: NCT06270836

A prospective, randomized, double-masked, sham-controlled, multi-center, two-arm, phase 3 study to evaluate the efficacy and safety of intravitreal Tarcocimab Tedromer in treatment naïve participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

JCHR (Protocol AF) “DRCR AF”
ClinicalTrials.gov Identifier: NCT04661358

A triple-masked, randomized trial to evaluate the effect of Fenofibrate, a cholesterol medication, compared with placebo for prevention of diabetic retinopathy (DR) worsening through 4 years of follow-up in eyes with mild to moderately severe non-proliferative diabetic retinopathy (NPDR).

Genentech “GR43828”
ISRCTN Registry Link: doi.org/10.1186/ISRCTN14152148

A phase I, multicenter, open-label study of the safety, tolerability, pharmacokinetics and
immunogenicity of intravitreal injections of RO7446603 alone and co-administered with
Aflibercept or Faricimab in patients with diabetic macular edema.

Quasar

ClinicalTrials.gov Identifier: NCT05850520

A Phase 3 Study of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion.

Unity Biotechnology, Inc. (Protocol UBX1325-04) “Aspire”

ClinicalTrials.gov Identifier: NCT06011798

A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema (Aspire).

Kodiak Sciences, Inc. (Protocol KS501P101) “Apex”

ClinicalTrials.gov Identifier:

A phase 2, multi-center, randomized, parallel-group study to assess the efficacy and safety of KHK4951 eye drops, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema (DME).

Eyebiotech, Ltd. (Protocol EYE-TIE-201) “EYE-TIE-201”

ClinicalTrials.gov Identifier: NCT06664502

A phase 1/2a 2-part study consisting of an open-label, multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO), and a dose-finding, double-masked, comparative safety, and preliminary efficacy study of intravitreal (IVT) EYE201 (Tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD).

Eyebiotech, Ltd. (Protocol EYE-RES-102) “Brunello”

ClinicalTrials.gov Identifier: NCT06571045

A randomized, double-masked, multi-center, 3-arm pivotal phase ⅔ study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5mg) in participants with diabetic macular edema (DME).

Oculis (Protocol DX221) “Diamond 2”

ClinicalTrials.gov Identifier: NCT06172257

A phase 3, double-masked, randomized, multi-center study of the efficacy and safety of OCS-01 eye drops in subjects with diabetic macular edema (DME).

Kyowa Kirin, Inc. (Protocol 4951-003) “KHK-003”

ClinicalTrials.gov Identifier: NCT06116916

A phase 2, multi-center, randomized, parallel-group study to assess the efficacy and safety of KHK4951 eye drops, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema (DME).

Bayer AG (Protocol 22153) “Quasar”

ClinicalTrials.gov Identifier: NCT05850520

Randomized, double-masked, active-controlled, Phase 3 study of the efficacy and safety of Aflibercept 8 mg in macular edema secondary to retinal vein occlusion.

Eyebiotech, Ltd. (Protocol EYE-TIE-201) “EYE-TIE-201”

ClinicalTrials.gov Identifier: NCT06664502

A phase 1/2a 2-part study consisting of an open-label, multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO), and a dose-finding, double-masked, comparative safety, and preliminary efficacy study of intravitreal (IVT) EYE201 (Tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD).

Kyoto Drug Discovery & Development Co., Ltd. (Protocol KDK-1101-002) “GION”

ClinicalTrials.gov Identifier: NCT06178055

A phase 2, double-masked, randomized, sham-controlled, multiple-dose study of the efficacy and safety of intravitreal KUS121 in the treatment of nonarteritic central retinal artery occlusion (CRAO).

(No studies currently enrolling)

Aura Biosciences, Inc. “Compass”

ClinicalTrials.gov Identifier: NCT06007690

A Phase 3 randomized, masked, controlled trial to evaluate efficacy and safety of Belzupacap Sarotalocan (AU-011) treatment compared to sham control in subjects with primary indeterminate lesion or small choroidal melanoma.

Priovant Therapeutics, Inc. (Protocol PVT-2201-303) “Clarity”

ClinicalTrials.gov Identifier: NCT06431373

A phase 3, randomized, double-masked, placebo-controlled study to investigate the safety and efficacy of oral brepocitinib in adults with active, non-infectious intermediate-, posterior-, and panuveitis.

F. Hoffman-La Roche Limited. (Protocol GP44467) “SatraGo-1”

ClinicalTrials.gov Identifier:

A phase 3, randomized, double-masked, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Satralizumab in participants with moderate-to-severe thyroid eye disease.

Genentech (Protocol GE43220) “Honu”

ClinicalTrials.gov Identifier: NCT05300724

Observational study of the progression of dry AMD patients.

Regeneron Pharmaceuticals. (Protocol VGFTe-HD-OD-2444) “Elara”

ClinicalTrials.gov Identifier:

A phase 3b single-arm study of aflibercept 8mg in participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Bayer (Protocol 20968) “PULSAR”

ClinicalTrials.gov Identifier: NCT04423718

A phase 2, double-masked, randomized, sham-controlled, multiple-dose study of the efficacy and safety of intravitreal KUS121 in the treatment of nonarteritic central retinal artery occlusion (CRAO).

F. Hoffmann La Roche/Genentech (Protocol GR40844) “AVONELLE-X”

ClinicalTrials.gov Identifier: NCT04777201

Faricimab vs. Aflibercept in Patients With wAMD.

F. Hoffmann La Roche/Genentech (Protocol GR40549) “Portal”

ClinicalTrials.gov Identifier: NCT03683251

A study to evaluate the long-term safety and tolerability of the port delivery system with Ranibizumab in patients with neovascular age-related macular degeneration.

Eyebiotech, Ltd. (Protocol EYE103-101) “Amarone”

ClinicalTrials.gov Identifier: NCT05919693

A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Clearside. (Protocol CLS1002-202) “Odyssey”

ClinicalTrials.gov Identifier: NCT05850520

A phase 2B study of suprachoroidal administered CLS-AX (Axitinib) in participants with neovascular age-related macular degeneration.

F. Hoffmann La Roche/Genentech (Protocol GR40844) “Lucerne”

Faricimab vs. Aflibercept in Patients With wAMD.

F. Hoffmann La Roche/Genentech (Protocol GR40398) “Rhine” Faricimab vs. Aflibercept in Patients With Diabetic Macular Edema

Novartis Pharmaceuticals (Protocol CRTH258B2301) “Kestrel”

Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Novo Nordisk (Protocol NN9535-4352) “Focus” – In collaboration with Texas Diabetes & Endocrinology

Semaglutide vs. placebo in Type II diabetics.

F. Hoffmann La Roche/Genentech (Protocol GR40548) “Archway”

Port Delivery System (PDS) vs. Ranibzumab in Patients With wAMD.

Ophthotech (Protocol OPH2005)

Anti-C5 aptamer in patients with Stargardt Disease.

Samsung Bioepis (Protocol SB11-G31-AMD)

Intravitreal SB11 (Proposed Ranibizumab biosimilar) compared to Ranibizumab alone in patients with wAMD.

Ophthotech (Protocol OPH2003)

Anti-C5 aptamer in patients with Geographic Atrophy.

DRCR/JAEB (Protocol W)

AntiVEGF in prevention of vision threatening Diabetic Retinopathy in high risk eyes.

Novartis (Protocol RFB002/Ranibizumab) “RAINBOW”

Ranibizumab vs laser in infants with ROP.

DRCR/JAEB (Protocol TX)

5 Year follow-up exam of subjects who completed DRCR protocol “T”, a comparison of Aflibercept, Bevacizumab and Ranibizumab in patients with DME.

DRCR/JAEB (Protocol AA)

Ultrawide-Field imaging vs traditional 7F fundus photography in patients with diabetic retinopathy in monitoring disease progression.

Unity Biotech “Envision”

UBX1325 vs aflibercept in the treatment of wAMD

Clearside Biomedical “Oasis”

Efficacy and safety of suprachoroidal injection of CLS-AX.

Santen Pharmaceutical Co. “Lumina”

Intravitreal DE-109 vs sham

Eyepoint EYP-2102-001

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

Genentech, Inc. (Protocol ML43000) “Belvedere"

Phase IV study designed to assess the response to treatment with SUSVIMO Q24W in patients with nAMD who have been previously treated with anti-VEGF agents other than ranibizumab.

Age Related Macular Degeneration:

• Bayer (Protocol 20968) “PULSAR”
  ClinicalTrials.gov Identifier: NCT04423718
  Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration.

• F. Hoffmann La Roche/Genentech (Protocol GR40844) “AVONELLE-X”
  ClinicalTrials.gov Identifier: NCT04777201
  Faricimab vs. Aflibercept in Patients With wAMD.

• F. Hoffmann La Roche/Genentech (Protocol GR40549) “Portal”
  ClinicalTrials.gov Identifier: NCT03683251
  A study to evaluate the long-term safety and tolerability of the port delivery system with Ranibizumab in patients with neovascular age-related macular degeneration.

• UNITY Biotechnology, Inc. (Protocol UBX1325-03) “Envision”
  A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration.

• EyePoint “Davio2
  A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD.

• Amarone
  A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

• Odyssey
  A phase 2B study of suprachoroidal administered CLS-AX (Axitinib) in participants with neovascular age-related macular degeneration.

-Henlius Bio. (Protocol HLX04-O-wAMD) “Henlius”**
A Phase I/II, Single-arm, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of HLX04-O Administered by Intravitreal Injection in Subjects With Wet Age Related Macular Degeneration (wAMD).

Non-Proliferative Diabetic Retinopathy:

• OcuTerra “DR:eam”
  A Phase 2 Randomized, Double-Masked, Vehicle- Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR).

• Hoffmann-La Roche (Protocol GR41675) “PAVILION”
  ClinicalTrials.gov Identifier: NCT04503551
  A Phase III Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy.

• Kodiak Sciences Inc. (Protocol KS301P106) “GLOW”
  Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR).

• Bayer “Neon"
  A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately
  severe to severe non-proliferative diabetic retinopathy

• Eyepoint “PAVIA"
  A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), compared to Sham

Diabetic Macular Edema

• Hoffmann-La Roche (Protocol GR40550) “Pagoda”
  ClinicalTrials.gov Identifier: NCT04108156
  A Phase III Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema.

• Adverum Biotechnologies, Inc. (Protocol CRTH258B2305) “INFINITY”
  ClinicalTrials.gov Identifier: NCT04418427
  A Phase 2 Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema.

• Oculis “Diamond
  This trial is a Phase 3 Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema.

• Kodiak “KS501P101
  ClinicalTrials.gov Identifier: Pending
  This is a Phase 1 Study to investigate the Safety, Tolerability, Bioactivity, and Pharmacokinetics of multiple intravitreal administrations of KSI-501 in Participants with Macular Edema.

Retinal Vein Occlusion

• Kodiak Sciences Inc. (Protocol KS301P103) “BEACON”
  Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).

• Hoffmann-La Roche (Protocol GR41984) “BALATON”
  A Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion.

Geographic Atrophy

• IVERIC bio, Inc. (Protocol ISEE2008)
  A Phase 3 Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.

• Ionis Pharmaceuticals, Inc. “Golden” (Protocol ISIS 696844-CS5)
  Phase 2 Placebo-Controlled Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD).

Treatment Studies for All Diseases

• Amgen “ABP938”
  An Open Label, Two-Arm Study in Subjects with Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe

Stargardt Disease

• Iveric Bio "OPH2005"
  A Phase 2b Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease.

OcuTerra “DR:eam

ClinicalTrials.gov Identifier:

A Phase 2 Randomized, Double-Masked, Vehicle- Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR).

Hoffmann-La Roche (Protocol GR41675) “PAVILION”

ClinicalTrials.gov Identifier: NCT04503551

A Phase III Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy.

Bayer (Protocol 20739) “Neon”

ClinicalTrials.gov Identifier: NCT04722991

A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to
investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately
severe to severe non-proliferative diabetic retinopathy

Hoffmann-La Roche (Protocol GR40550) “Pagoda”

ClinicalTrials.gov Identifier: NCT04108156

A Phase III Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema. \

Adverum Biotechnologies, Inc. (Protocol CRTH258B2305) “INFINITY”

ClinicalTrials.gov Identifier: NCT04418427

A Phase 2 Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema.

Kodiak “KS501P101”

ClinicalTrials.gov Identifier:

A phase 1/1b study to investigate the safety, tolerability, bioactivity, and pharmacokinetics of multiple intravitreal administrations of KSI-501 in participants with diabetic macular edema (DME).

Valo Health (Protocol OPL-0401-201) “Spectra”

ClinicalTrials.gov Identifier: NCT05393284

A phase 2, randomized, double-masked, placebo-controlled, multicenter study to investigate the efficacy and safety of oral OPL-0401, a selective inhibitor of Rho (Ras homolog)-associated kinase, inhibiting ROCK1 and ROCK2 in patients with type 1 or 2 diabetes mellitus who have non-proliferative diabetic retinopathy (NPDR) with or without DME.

Genentech, Inc. (ML43601) “Magic”

ClinicalTrials.gov Identifier: NCT05681884

A triple-masked, randomized trial to evaluate the effect of Fenofibrate, a cholesterol medication, compared with placebo for prevention of diabetic retinopathy (DR) worsening through 4 years of follow-up in eyes with mild to moderately severe non-proliferative diabetic retinopathy (NPDR).

(No studies currently enrolled)

IVERIC bio, Inc. (Protocol OPH2005) “STGD1”

ClinicalTrials.gov Identifier: NCT03364153

A Phase 2b Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease.

IVERIC bio, Inc. (Protocol ISEE2008)

ClinicalTrials.gov Identifier: NCT04435366

A Phase 3 Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Ionis Pharmaceuticals, Inc. “Golden” (Protocol ISIS 696844-CS5)

ClinicalTrials.gov Identifier: NCT03815825

Phase 2 Placebo-Controlled Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD).

Genentech “Honu”

ClinicalTrials.gov Identifier: NCT05300724

Observational study of the progression of dry AMD patients.

Opthea (Protocol OPT-302-1002)

Intravitreal OPT-302 in combination with Ranibizumab, compared to Ranibizumab alone in patients with wAMD.

Allergan (Protocol 1771-201-008) “Maple”

Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration.

Allergan (Protocol 150998-006) “SEQUOIA”

Abicipar vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.

Alcon (Protocol RTH258-C001) “HAWK”

RTH258 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.

F. Hoffmann La Roche/Genentech (Protocol GX29176) “CHROMA” Phase III

Lampalizumab intravitreal injection vs sham in patients with Geographic Atrophy due to Dry AMD.

Allergan (Protocol 190342-038) “BEACON”

Brimonidine DDS vs Sham in patients with Geographic Atrophy due to Dry AMD.

Regeneron (Protocol R910-3-AMD-1517) “ONYX”

Co-formulation anti-Ang2+Aflibercept for patients with treatment-naïve CNV.

F. Hoffmann La Roche/Genentech (Protocol BP29647) “AVENUE”

RO6867461 vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.

Regeneron (Protocol R2176-3-AMD-1417) “CAPELLA”

REGN2176-3 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.

Ophthotech (Protocol OPH1002) “ECLIPSE” Phase III

Intravitreal injections of FOVISTA in combination with Lucentis versus Lucentis as monotherapy in patients with treatment-naïve Wet AMD.

LPath (Protocol LT1009-Oph-003) “NEXUS” Phase 2A

Intravitreal ISONEP (Sonepcizumab LT-1009) as monotherapy or adjunctive therapy to Lucentis, Avastin or Eylea versus Lucentis, Avastin or Eylea as monotherapy in patients with Wet AMD.

NeoVista (Protocol NVI-114) “CABERNET”

Prospective study of the Epi-Rad90 ophthalmic system in patients with subfoveal CNV secondary to AMD.

Regeneron (Protocol VGFT-OD-0910.03)

Safety and tolerability extension study of intravitreal VEGF Trap-Eye in patients with CVN secondary to AMD.

Regeneron (Protocol VGFT-OD-0606) “VIEW”

Safety and efficacy of intravitreal VEGF Trap versus ranibizumab in patients with CNV secondary to AMD.

Genentech (Protocol FVF3426g) “HORIZON”

Intravitreal ranibizumab extension study for patients who have completed a Genentech ranibizumab trial.

Genentech (Protocol FVF4579g) “HARBOR”

Safety and efficacy of 0.5mg and 2.0mg ranibizumab intravitreal injection administered monthly versus as-needed in patients with subfoveal CNV secondary to AMD.

GlaxoSmithKline (Protocol MD7110852)

Dose-evaluation study of pazopanib eye drops versus ranibizumab in patients with CNV secondary to AMD.

Acucela (Protocol 4429-201)

Safety and tolerability of oral ACU-4429 in patients with Dry AMD.

Allergan (Protocol 190342-032D-03)

Safety and efficacy of Brimonidine Tartrate PS DDS in patients with geographic atrophy.

Allergan (Protocol 206207-019)

PS DDS with ranibizumab in patients with CNV secondary to AMD

Allergan (Protocol 211745-001-01) “SIRIUS”

Safety and efficacy of intravitreal AGN211745 in patients with CNV secondary to AMD.

OPKO (Protocol “COBALT”)

Intravitreal bevasiranib versus Lucentis in patients with CNV secondary to AMD.

Genentech (Protocol FVF2587g) “ANCHOR”

Intravitreal ranibizumab versus Visudyne PDT in patients with CNV secondary to AMD.

Genentech (Protocol FVF2598g) “MARINA”

Intravitreal ranibizumab versus sham in occult CNV secondary to AMD.

Genentech (Protocol FVF3192g) “PIER”

Intravitreal ranibizumab in patients with minimally classic CNV secondary to AMD.

Genentech (Protocol FVF3689g) “SAILOR”

Intravitreal ranibizumab in patients with naïve or previously treated CNV secondary to AMD.

Eyetech, Inc./Pfizer (Protocol 1023) “LEVEL”

Intravitreal Macugen in patients with stable, previously treated CNV secondary to AMD.

Alcon Research , Ltd. (Protocol C-02-60)

Juxtascleral anacortave acetate versus sham CNV risk reduction study in patients with Dry AMD.

Alcon Research, Ltd. (Protocol C-01-99)

Juxtascleral anacortave acetate versus sham in patients with predominantly classic CNV secondary to AMD.

CIBA (Protocol BPD OCR-005) “VAM”

Visudyne T-IND study in patients with CNV secondary to AMD.

Miravant/Pharmacia (Protocol SNET2-98EA004)

SnET2 Photodynamic therapy versus sham in patients with CNV secondary to AMD.

Novartis Pharmaceuticals (Protocol CRTH258A2303) “TALON”

Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Age Related Macular Degeneration.

Kodiak Science, Inc. (Protocol KSI301-P107) “Daylight

This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD).

Graybug Vision, Inc. (Protocol GBV-102-002) “Altissimo”

GB-102 vs. Aflibercept in Patients With wAMD.

Kodiak Science, Inc. (Protocol KSI301-P107) “Daylight”

This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD).

UNITY Biotechnology, Inc. (Protocol UBX1325-03) “Envision”

A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration.

Novartis Pharmaceuticals (Protocol CRTH258A2303) “TALON”

A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration.

Xbrane Biopharma AB (Protocol XBR1001) “Xplore”

Xlucane vs. Ranibzumab in Patients With wAMD.

Novartis Pharmaceuticals (Protocol CRTH258AUS04) “Merlin”

Intravitreal Brolucizumab vs. Aflibercept in wAMD patients with retinal fluid despite frequent anti-VEGF injections.

Chengdu Kanghong Biotech (Protocol KHB-1802) “Panda-2"

Intravitreal Conbercept vs. Aflibercept in patients with treatment-naïve CNV due to wAMD.

University of California, San Francisco (Protocol METforMIN)

Metformin for the Minimization of Geographic Atrophy Progression in Patients with AMD.

F. Hoffmann La Roche/Genentech (Protocol GR40844) “Lucerne”

Faricimab vs. Aflibercept in Patients With wAMD.

F. Hoffmann La Roche/Genentech (Protocol GR40398) “Rhine”

Faricimab vs. Aflibercept in Patients With Diabetic Macular Edema

F. Hoffmann La Roche/Genentech (Protocol GR40548) “Archway”

Port Delivery System (PDS) vs. Ranibzumab in Patients With wAMD.

Ophthotech (Protocol OPH2005)

Anti-C5 aptamer in patients with Stargardt Disease.

Samsung Bioepis (Protocol SB11-G31-AMD)

Intravitreal SB11 (Proposed Ranibizumab biosimilar) compared to Ranibizumab alone in patients with wAMD.

Ophthotech (Protocol OPH2003)

Anti-C5 aptamer in patients with Geographic Atrophy.

Novartis (Protocol RFB002/Ranibizumab) “RAINBOW”

Ranibizumab vs laser in infants with ROP.

DRCR/JAEB (Protocol TX)

5 Year follow-up exam of subjects who completed DRCR protocol “T”, a comparison of Aflibercept, Bevacizumab and Ranibizumab in patients with DME.

Opthea (Protocol OPT-302-1002)

Intravitreal OPT-302 in combination with Ranibizumab, compared to Ranibizumab alone in patients with wAMD.

Allergan (Protocol 1771-201-008) “Maple”

Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration.

Allergan (Protocol 150998-006) “SEQUOIA”

Abicipar vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.

Alcon (Protocol RTH258-C001) “HAWK”

RTH258 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.
F. Hoffmann La Roche/Genentech (Protocol GX29176) “CHROMA” Phase III
Lampalizumab intravitreal injection vs sham in patients with Geographic Atrophy due to Dry AMD.

Allergan (Protocol 190342-038) “BEACON”

Brimonidine DDS vs Sham in patients with Geographic Atrophy due to Dry AMD.

Regeneron (Protocol R910-3-AMD-1517) “ONYX”

Co-formulation anti-Ang2+Aflibercept for patients with treatment-naïve CNV.

F. Hoffmann La Roche/Genentech (Protocol BP29647) “AVENUE”

RO6867461 vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.

Regeneron (Protocol R2176-3-AMD-1417) “CAPELLA”

REGN2176-3 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.

Ophthotech (Protocol OPH1002) “ECLIPSE” Phase III

Intravitreal injections of FOVISTA in combination with Lucentis versus Lucentis as monotherapy in patients with treatment-naïve Wet AMD.

LPath (Protocol LT1009-Oph-003) “NEXUS” Phase 2A
Intravitreal ISONEP (Sonepcizumab LT-1009) as monotherapy or adjunctive therapy to Lucentis, Avastin or Eylea versus Lucentis, Avastin or Eylea as monotherapy in patients with Wet AMD.

NeoVista (Protocol NVI-114) “CABERNET”

Prospective study of the Epi-Rad90 ophthalmic system in patients with subfoveal CNV secondary to AMD.

Regeneron (Protocol VGFT-OD-0910.03)

Safety and tolerability extension study of intravitreal VEGF Trap-Eye in patients with CVN secondary to AMD.

Regeneron (Protocol VGFT-OD-0606) “VIEW”

Safety and efficacy of intravitreal VEGF Trap versus ranibizumab in patients with CNV secondary to AMD.

Genentech (Protocol FVF3426g) “HORIZON”

Intravitreal ranibizumab extension study for patients who have completed a Genentech ranibizumab trial.

Genentech (Protocol FVF4579g) “HARBOR”

Safety and efficacy of 0.5mg and 2.0mg ranibizumab intravitreal injection administered monthly versus as-needed in patients with subfoveal CNV secondary to AMD.

GlaxoSmithKline (Protocol MD7110852)

Dose-evaluation study of pazopanib eye drops versus ranibizumab in patients with CNV secondary to AMD.

Acucela (Protocol 4429-201)

Safety and tolerability of oral ACU-4429 in patients with Dry AMD.

Allergan (Protocol 190342-032D-03)

Safety and efficacy of Brimonidine Tartrate PS DDS in patients with geographic atrophy.

Allergan (Protocol 206207-019)

PS DDS with ranibizumab in patients with CNV secondary to AMD

Allergan (Protocol 211745-001-01) “SIRIUS”

Safety and efficacy of intravitreal AGN211745 in patients with CNV secondary to AMD.

OPKO (Protocol “COBALT”)

Intravitreal bevasiranib versus Lucentis in patients with CNV secondary to AMD.

Genentech (Protocol FVF2587g) “ANCHOR”

Intravitreal ranibizumab versus Visudyne PDT in patients with CNV secondary to AMD.

Genentech (Protocol FVF2598g) “MARINA”

Intravitreal ranibizumab versus sham in occult CNV secondary to AMD.

Genentech (Protocol FVF3192g) “PIER”

Intravitreal ranibizumab in patients with minimally classic CNV secondary to AMD.

Genentech (Protocol FVF3689g) “SAILOR”

Intravitreal ranibizumab in patients with naïve or previously treated CNV secondary to AMD.

Eyetech, Inc./Pfizer (Protocol 1023) “LEVEL”

Intravitreal Macugen in patients with stable, previously treated CNV secondary to AMD.

Alcon Research , Ltd. (Protocol C-02-60)

Juxtascleral anacortave acetate versus sham CNV risk reduction study in patients with Dry AMD.

Alcon Research, Ltd. (Protocol C-01-99)

Juxtascleral anacortave acetate versus sham in patients with predominantly classic CNV secondary to AMD.

CIBA (Protocol BPD OCR-005) “VAM”

Visudyne T-IND study in patients with CNV secondary to AMD.

Miravant/Pharmacia (Protocol SNET2-98EA004)

SnET2 Photodynamic therapy versus sham in patients with CNV secondary to AMD.

Kodiak Science, Inc. (Protocol KSI-CL-102) “Dazzle”

Phase 2b/3 Active Comparator-controlled Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration.

Novartis Pharmaceuticals (Protocol CRTH258A2303) “TALON”

Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Age Related Macular Degeneration.

EyePoint Pharmaceuticals, Inc. (Protocol EYP-1901-001) “DAVIO”

A Phase 1, Open-Label Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD.

F. Hoffmann La Roche/Genentech (Protocol GR40844) “Lucerne”

Faricimab vs. Aflibercept in Patients With wAMD.

Regeneron (Protocol VGFTe-OD-1411) “PANORAMA”

Aflibercept vs sham in patients with NPDR.

Aerpio Therapeutics, Inc. (Protocol AKB-9779-CI-5001) “TIME-2B”

A Novel Tie 2 Activator, AKB-9778, use once or twice daily vs sham in patients with NPDR.

Clearside Biomedical (Protocol CLS1004-201) “TYBEE”

Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in DME.

Roche (Protocol BP30099) “BOULEVARD”

Anti-VEGF + anti-Ang2 for patients with DME.

Regeneron (Protocol R910-3-DME-1518) “RUBY”

Co-formulation anti-Ang2+Aflibercept for patients with DME.

Allegro (Protocol DME-202B) “Del Mar” Stage 1 and 2

Luminate vs Avastin in patients with DME.

Allegro (Protocol PVD-202) “Pacific”

Luminate vs BSS for PVD inducement in patients with NPDR.

Allergan (Protocol 150998-004) “PALM”

Evaluation of Abicipar Pegol (AGN-150998) versus ranibizumab in patients with vision loss due to diabetic macular edema.

Aerpio Therapeutics, Inc. (Protocol AKB-9778-CI-2003)

Safety and efficacy of daily, subcutaneous AKB-9778 injections as monotherapy or adjunctive therapy to ranibizumab vs. ranibizumab as monotherapy in patients with diabetic macular edema.

DRCR/JAEB (Protocol U)

Evaluation of combination corticosteroid plus anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes.

Regeneron (Protocol VGFT-OD-1009.01) “VISTA”

Safety and efficacy of intravitreal VEGF Trap-Eye in patients with diabetic macular edema.

iCo Therapeutics (Protocol 2010-007-03-DME) “iDEAL”

Intravitreal injections of iCo-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in patients with foveal diabetic macular edema.

DRCR/JAEB (Protocol T)

Comparative effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab in patients with diabetic macular edema.

DRCR/JAEB (Protocol GEN)

Genes in Diabetic Retinopathy Project.

DRCR/JAEB (Protocol V)

Prompt laser + deferred aflibercept vs. Observation + deferred aflibercept vs. Prompt aflibercept, (1:1:1), for the treatment of diabetic macular edema in treatment-naïve patients with very good vision (20/25 or better).

DRCR (Protocol S)

Prompt PRP versus intravitreal ranibizumab with deferred PRP in patients with proliferative diabetic retinopathy.

Allergan (Protocol 206207-024)

Comparing the safety and efficacy of dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema.

Genentech (Protocol FVF4170g) “RISE”

Safety and efficacy of intravitreal ranibizumab versus sham injection in patients with clinically significant macular edema secondary to diabetes mellitus.

Allergan (Protocol 206207-011)

Dexamethasone PS DDS versus sham in patients with diabetic macular edema.

DRCR/JAEB (Protocol 1A)

Modified laser treatment in patients with diabetic macular edema.

DRCR/JAEB (Protocol B)

Observation of diabetic macular edema following scatter laser therapy.

DRCR/JAEB (Protocol F)

Triamcinolone with focal laser in patients with diabetic macular edema.

Allergan (Protocol 206207-018)

PS DDS in patients with diabetic macular edema status post vitrectomy.

Alimera Sciences , Inc. (Protocol C-01-05-001) “FAME”

Intravitreal Fluocinolone Acetonide versus sham in patients with diabetic macular edema.

Oxular “Cape”

A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered with the Oxulumis® Ophthalmic Administration Device in Subjects with Diabetic Macular Edema.

Oxurion “Kalahari” (Protocol THR-149-002)
This is a Phase 2 Study of the Efficacy and Safety of THR-149 versus aflibercept in Subjects With Diabetic Macular Edema.

Kodiak Sciences Inc. (Protocol KS301P106) “GLOW”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR).

Kodiak Sciences Inc (Protocol KS301P104) “GLEAM”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).

Hoffmann-La Roche (Protocol KS301P105) “GLIMMER”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).

Hoffmann-La Roche (Protocol GR41987) “Rhone-X”
Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema.

Novartis Pharmaceuticals (Protocol CRTH258D2301) “CONDOR”
Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy.

Kodiak Sciences Inc. (Protocol KS301P106) “GLOW”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR).

Kodiak Sciences Inc (Protocol KS301P104) “GLEAM”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).

Hoffmann-La Roche (Protocol KS301P105) “GLIMMER”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).

Hoffmann-La Roche (Protocol GR41987) “Rhone-X”
Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema.

Novartis Pharmaceuticals (Protocol CRTH258D2301) “CONDOR”
Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

DRCR/JAEB (Protocol W)
AntiVEGF in prevention of vision threatening Diabetic Retinopathy in high risk eyes.

DRCR/JAEB (Protocol AA)
Ultrawide-Field imaging vs traditional 7F fundus photography in patients with diabetic retinopathy in monitoring disease progression.

Novartis Pharmaceuticals (Protocol CRTH258B2301) “Kestrel”
Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Novo Nordisk (Protocol NN9535-4352) “Focus” – In collaboration with Texas Diabetes & Endocrinology
Semaglutide vs. placebo in Type II diabetics.

DRCR/JAEB (Protocol AE)
Photobiomodulation compared with sham for the Treatment of CI-DME

Opthea (Protocol OPT-302-1003)
Intravitreal OPT-302 in combination with Aflibercept, compared to Aflibercept alone in patients with Diabetic Macular Edema.

DRCR/JAEB (Protocol AC)
Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

Regeneron (Protocol VGFTe-OD-1411) “PANORAMA”
Aflibercept vs sham in patients with NPDR.

Aerpio Therapeutics, Inc. (Protocol AKB-9779-CI-5001) “TIME-2B”
A Novel Tie 2 Activator, AKB-9778, use once or twice daily vs sham in patients with NPDR.

Clearside Biomedical (Protocol CLS1004-201) “TYBEE”
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in DME.

Roche (Protocol BP30099) “BOULEVARD”
Anti-VEGF + anti-Ang2 for patients with DME.

Oxular “Cape”
A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered with the Oxulumis® Ophthalmic Administration Device in Subjects with Diabetic Macular Edema.

Oculis “Diamond” (Protocol DX219)
This trial is a Phase 3 Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema.

Regeneron (Protocol R910-3-DME-1518) “RUBY”
Co-formulation anti-Ang2+Aflibercept for patients with DME.

Allegro (Protocol DME-202B) “Del Mar” Stage 1 and 2
Luminate vs Avastin in patients with DME.

Allegro (Protocol PVD-202) “Pacific”
Luminate vs BSS for PVD inducement in patients with NPDR.

Allergan (Protocol 150998-004) “PALM”
Evaluation of Abicipar Pegol (AGN-150998) versus ranibizumab in patients with vision loss due to diabetic macular edema.

Aerpio Therapeutics, Inc. (Protocol AKB-9778-CI-2003)
Safety and efficacy of daily, subcutaneous AKB-9778 injections as monotherapy or adjunctive therapy to ranibizumab vs. ranibizumab as monotherapy in patients with diabetic macular edema.

DRCR/JAEB (Protocol U)
Evaluation of combination corticosteroid plus anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes.

Regeneron (Protocol VGFT-OD-1009.01) “VISTA”
Safety and efficacy of intravitreal VEGF Trap-Eye in patients with diabetic macular edema.

iCo Therapeutics (Protocol 2010-007-03-DME) “iDEAL”
Intravitreal injections of iCo-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in patients with foveal diabetic macular edema.

DRCR/JAEB (Protocol T)
Comparative effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab in patients with diabetic macular edema.

DRCR/JAEB (Protocol GEN)
Genes in Diabetic Retinopathy Project.

DRCR/JAEB (Protocol V)
Prompt laser + deferred aflibercept vs. Observation + deferred aflibercept vs. Prompt aflibercept, (1:1:1), for the treatment of diabetic macular edema in treatment-naïve patients with very good vision (20/25 or better).

DRCR (Protocol S)
Prompt PRP versus intravitreal ranibizumab with deferred PRP in patients with proliferative diabetic retinopathy.

Allergan (Protocol 206207-024)
Comparing the safety and efficacy of dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema.

Hoffmann-La Roche (Protocol GR40398) “RHINE”
PA Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE).

Genentech (Protocol FVF4170g) “RISE”
Safety and efficacy of intravitreal ranibizumab versus sham injection in patients with clinically significant macular edema secondary to diabetes mellitus.

Allergan (Protocol 206207-011)
Dexamethasone PS DDS versus sham in patients with diabetic macular edema.

DRCR/JAEB (Protocol 1A)
Modified laser treatment in patients with diabetic macular edema.

DRCR/JAEB (Protocol B)
Observation of diabetic macular edema following scatter laser therapy.

DRCR/JAEB (Protocol F)
Triamcinolone with focal laser in patients with diabetic macular edema.

Allergan (Protocol 206207-018)
PS DDS in patients with diabetic macular edema status post vitrectomy.

Alimera Sciences , Inc. (Protocol C-01-05-001) “FAME”
Intravitreal Fluocinolone Acetonide versus sham in patients with diabetic macular edema.

Novartis Pharmaceuticals (Protocol CRTH258B2305) “KINGFISHER”
Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema.

Adverum Biotechnologies, Inc. (Protocol CRTH258B2305) “INFINITY”
A Phase 2 Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema.

Regeneron Pharmaceuticals (Protocol VGFTe-HD-DME-1934) “PHOTON”
Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema.

Clearside Biomedical (Protocol CLS1003-302) “Topaz”

Supra-choroidal Triamcinolone with Intravitreal Anti-VEGF vs sham Suprachoroidal procedure with Intravitreal Anti-VEGF in RVO with ME.

Clearside Biomedical (Protocol CLS1003-301) “SAPPHIRE”

Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in RVO with ME.

Allergan (Protocol 208397-001)

Safety and efficacy of a single dose of AGN-208397 in patients with macular edema due to retinal vein occlusion.

Genentech (Protocol FVF4165g) “BRAVO”

Ranibizumab versus sham in patients with branch retinal vein occlusion.

Genentech (Protocol FVF4166g) “CRUISE”

Intravitreal ranibizumab versus sham in patients with central retinal vein occlusion.

Hoffmann-La Roche (Protocol GR41986) “COMINO”

A Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.

Genentech (Protocol FVF4967g ) “SHORE”

Dosing regimens of intravitreal ranibizumab in patients with macular edema secondary to retinal vein occlusion.

Allergan (Protocol 206207-009)

Intravitreal dexamethasone PS DDS versus sham in patients with central or branch retinal vein occlusion.

Kodiak Sciences Inc. (Protocol KS301P103)

Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).

Aerie Pharmaceuticals, Inc. (Protocol AR-1105-CS201) “Orion”
This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO).

Clearside Biomedical (Protocol CLS1003-302) “Topaz”
Supra-choroidal Triamcinolone with Intravitreal Anti-VEGF vs sham Suprachoroidal procedure with Intravitreal Anti-VEGF in RVO with ME.

Clearside Biomedical (Protocol CLS1003-301) “SAPPHIRE”
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in RVO with ME.

Allergan (Protocol 208397-001)
Safety and efficacy of a single dose of AGN-208397 in patients with macular edema due to retinal vein occlusion.

Genentech (Protocol FVF4165g) “BRAVO”
Ranibizumab versus sham in patients with branch retinal vein occlusion.

Genentech (Protocol FVF4166g) “CRUISE”
Intravitreal ranibizumab versus sham in patients with central retinal vein occlusion.

Hoffmann-La Roche (Protocol GR41986) “COMINO”
A Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.

Genentech (Protocol FVF4967g ) “SHORE”
Dosing regimens of intravitreal ranibizumab in patients with macular edema secondary to retinal vein occlusion.

Allergan (Protocol 206207-009)
Intravitreal dexamethasone PS DDS versus sham in patients with central or branch retinal vein occlusion.

Kodiak Sciences Inc. (Protocol KS301P103) “BEACON”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).

Hoffmann-La Roche (Protocol GR41984) “BALATON”
A Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion.

Mallinckrodt (Protocol MNK61074105)
Acthar in patients with severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.

Eyegate (Protocol EGP-437-006)
Iontophorectic dexamethasone for non-infectious anterior Uveitis.

Clearside Biomedical (Protocol CLS1001-301) “Peachtree”
Supra-choroidal Triamcinolone for non-infectious Uveitis.

Santen (Protocol 32-007) “SAKURA”
Safety and efficacy of DE-109 for the treatment of active, non-infectious posterior segment uveitis.

EyeGate (Protocol EGP-437-004)
Safety and efficacy of iontophoretic dexamethasone phosphate compared to prednisolone acetate 1% in patients with non-infectious anterior segment uveitis.

Mallinckrodt (Protocol MNK61074105)

Acthar in patients with severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.

Eyegate (Protocol EGP-437-006)

Iontophorectic dexamethasone for non-infectious anterior Uveitis.

Clearside Biomedical (Protocol CLS1001-301) “Peachtree”

Supra-choroidal Triamcinolone for non-infectious Uveitis.

Santen (Protocol 32-007) “SAKURA”

Safety and efficacy of DE-109 for the treatment of active, non-infectious posterior segment uveitis.

EyeGate (Protocol EGP-437-004)

Safety and efficacy of iontophoretic dexamethasone phosphate compared to prednisolone acetate 1% in patients with non-infectious anterior segment uveitis.

Alcon Research, LTD. (Protocol C-04-18)

Evaluation of BSS irrigating solution during vitrectomy.

Inspire (Protocol 06-102)

Intravitreal Denufosol in patients with rhegmatogenous retinal detachment.

Alcon Research, LTD. (Protocol C-04-18)

Evaluation of BSS irrigating solution during vitrectomy.

Inspire (Protocol 06-102)

Intravitreal Denufosol in patients with rhegmatogenous retinal detachment.

Allegro Ophthalmics, LLC (Protocol VMA-202)

Safety and efficacy of intravitreal ALG-1001 vs. BSS injection in patients with symptomatic vitreomacular adhesion.

ThromboGenics (Protocol TG-MV-006) “MIVI-TRUST”

Microplasmin intravitreal injection versus sham injection in patients with vitreomacular traction.

Allegro Ophthalmics, LLC (Protocol VMA-202)

Safety and efficacy of intravitreal ALG-1001 vs. BSS injection in patients with symptomatic vitreomacular adhesion.

ThromboGenics (Protocol TG-MV-006) “MIVI-TRUST”

Microplasmin intravitreal injection versus sham injection in patients with vitreomacular traction.

DigiSight (Protocol DS2001510k) “PAXOS Checkup”

Mobile device self visual acuity testing vs ETDRS.

Rohrer (Protocol 513403-T)

Pharmacokinetics and safety of lomefloxacin eye drops.

Parke-Davis (Protocol 919-220-0)

A multiple dose safety study on enoxacin eye drops.

Otsuka (Protocol 67-90-201)

Pharmacokinetics and safety of OPC-14117 eye drops.

Pharmos (Protocol P-5604:107)

Safety and efficacy of loteprednol etabonate in patients with GPC secondary to contact lens wear.

Genentech, Inc. (Protocol GR40973) “GALLEGO”

A Phase II Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Genentech, Inc. (Protocol GR40973) “GALLEGOLE”

Phase II Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Diopsys, Inc. “Indigo”

Evaluation of retinal function in eyes with diabetic retinopathy treated with anti-VEGF using Flicker ERG

Amgen “ABP938”

An Open Label, Two-Arm Study in Subjects with Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe

Verily Life Sciences, LLC “ARDA-003”

Evaluation of investigational retinal imaging camera study

DigiSight (Protocol DS2001510k) “PAXOS Checkup”

Mobile device self visual acuity testing vs ETDRS.

Rohrer (Protocol 513403-T)

Pharmacokinetics and safety of lomefloxacin eye drops.

Parke-Davis (Protocol 919-220-0)

A multiple dose safety study on enoxacin eye drops.

Otsuka (Protocol 67-90-201)

Pharmacokinetics and safety of OPC-14117 eye drops.

Pharmos (Protocol P-5604:107)

Safety and efficacy of loteprednol etabonate in patients with GPC secondary to contact lens wear.

Genentech, Inc. (Protocol GR40973) “GALLEGOLE”

Phase II Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Genentech, Inc. (Protocol GR40973) “GALLEGO”

A Phase II Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.